Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 10;13(22):5619.
doi: 10.3390/cancers13225619.

Lipid Nanocarriers for Hyperproliferative Skin Diseases

Eliana B Souto  1 , Ana L R de Souza  2 , Fernanda K Dos Santos  2 , Elena Sanchez-Lopez  3   4 , Amanda Cano  3   4 , Aleksandra Zielińska  5 , Rafał Staszewski  6 , Jacek Karczewski  7   8 , Maria P D Gremião  2 , Marlus Chorilli  2
Affiliations
Review

Lipid Nanocarriers for Hyperproliferative Skin Diseases

Eliana B Souto et al. Cancers (Basel). .

Abstract

Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD.

Keywords: antiproliferative drugs; hyperproliferative skin diseases; lipid nanoparticles; liposomes; skin cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the encapsulation of active pharmaceutical ingredients (APIs) in different types of lipid nanocarriers [own drawing].
Figure 2
Figure 2
Different pathways of skin penetration of nanoparticles and superficial spreading melanoma (own drawing).
See this image and copyright information in PMC

References

    1. Pohla L., Ottas A., Kaldvee B., Abram K., Soomets U., Zilmer M., Reemann P., Jaks V., Kingo K. Hyperproliferation is the main driver of metabolomic changes in psoriasis lesional skin. Sci. Rep. 2020;10:1–7. doi: 10.1038/s41598-020-59996-z. - DOI - PMC - PubMed
    1. Thatikonda S., Pooladanda V., Sigalapalli D.K., Godugu C. Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation. Cell Death Dis. 2020;11:17–21. doi: 10.1038/s41419-019-2212-y. - DOI - PMC - PubMed
    1. Sahu S.K., Raj R., Raj P.M., Alpana R. Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review. Curr. Drug Ther. 2020;15:283–298. doi: 10.2174/1574885513666181112153213. - DOI
    1. Kim S.C., Yoon H.J., Lee J.W., Yu J., Park E.-S., Chi S.-C. Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. Int. J. Pharm. 2005;293:303–310. doi: 10.1016/j.ijpharm.2005.01.011. - DOI - PubMed
    1. Prow T.W., Grice J.E., Lin L.L., Faye R., Butler M., Becker W., Wurm E.M.T., Yoong C., Robertson T.A., Soyer H.P., et al. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev. 2011;63:470–491. doi: 10.1016/j.addr.2011.01.012. - DOI - PubMed

LinkOut - more resources